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EFFECT OF A PRICE TRANSPARENCY INTERVENTION
IN THE ELECTRONIC HEALTH RECORD ON CLINICIAN
ORDERING OF INPATIENT LABORATORY TESTS
Mina S. Sedrak, Jennifer S. Myers, Dylan S. Small, Irving Nachamkin, Justin B. Ziemba, Dana Murray, Gregory W. Kurtzman,
Jingsan Zhu, Wenli Wang, Deborah Mincarelli, Daniel Danoski, Brian P. Wells, Jeffrey S. Berns, Patrick J. Brennan,
C. William Hanson, Jessica Dine, Mitesh S. Patel
JAMA Internal Medicine, April 2017

KEYFINDINGS

Despite the promise of price transparency, clinicians did not change their ordering of inpatient lab tests when Medicare
allowable fees were displayed in the electronic health record at the time of order entry.
THE QUESTION
With estimates that nearly 30% of laboratory testing in the United States
is wasteful, health systems are considering making clinicians more aware
of the costs of the tests they order. Price transparency, at the time of
ordering, may encourage clinicians to consider the cost of their decisions.
This study sought to answer the question: if clinicians knew the cost of the
tests they order in the hospital, would they change their ordering behavior?

THE STUDY
This year-long randomized clinical trial was conducted at three hospitals
within the University of Pennsylvania Health System in Philadelphia. It
analyzed the ordering practices of physicians, nurse practitioners, and
physician assistants, but did not differentiate between these clinicians.

The research team conducted subgroup comparisons of differences in
ordering behavior for patients with varying comorbidities, for those who
had an intensive care unit (ICU) stay, and for tests from the highest and
lowest cost brackets.

THE FINDINGS
The mean number of tests per patient day did not change significantly
in the intervention group compared to the control group over time. As
shown, the mean number of tests ordered per patient-day remained
virtually unchanged in both the intervention and control group. Even after
UNADJUSTED NUMBER OF INPATIENT LABORATORY TESTS
ORDERED PER PATIENT-DAY BY GROUP AND MONTH

The analysis included a one-year pre-intervention period and a one-year
intervention period. The authors randomized 60 lab tests to two groups:
one that displayed Medicare allowable fees at the time of order and the
other that did not.
The primary outcome was the number of tests ordered per patient-day,
after adjusting for patient characteristics and other variables. The authors
also looked at the associated fees per patient-day.

Source: Sedrak et al., JAMA Internal Medicine.
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adjusting for other factors, there was no significant change in the mean
number of tests ordered or mean fees attributable to the intervention.
In subanalyses, the authors found a relative decrease in test ordering for
patients with an ICU stay and a relative increase for patients without an
ICU stay, and relative decrease in test ordering of tests in the top-quartile
of fees and a relative increase of tests in the bottom-quartile of fees.

THE IMPLICATIONS
Prior evidence has been inconsistent on the effectiveness of price
transparency as a way to influence medical decision-making. This study
provides further evidence that price transparency, by itself, is not likely to
reduce ordering of wasteful tests in the hospital.
A number of explanations may account for these findings and point
the way toward more effective interventions. First, the allowable fees in
the intervention were displayed regardless of the clinical scenario. The
presence of this information for appropriate tests may have diminished its
impact when tests were inappropriate. Future efforts might target price
transparency more selectively.
Second, the intervention might have had reduced salience because it did
not consider clinician practice habits. In a qualitative analysis at one of the
hospital sites, 91% of resident physicians reported that unnecessary lab
testing was due to the habit of entering repeating daily lab test orders on
the patient’s first day of admission. If repeating orders were entered at
admission, the clinician would not need to place another order and thus
would not be presented with price transparency information when it would
be most salient. This might explain the effects of the intervention when
patients had an ICU stay. Because health care decisions are changing
more rapidly in this setting, clinicians may be less likely to rely on repeating
orders and therefore may have been exposed to the intervention more
often. Pairing price transparency information with interventions reducing
the use of repeating test orders could address this problem.
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This could explain the small but significant decrease in ordering for the
most expensive tests and the small but significant increase in ordering for
the least expensive tests. Other ways to frame price transparency, such as
comparisons of differences in price between options, using other forms
of price, such as charges, or targeting only more expensive tests, may be
needed.
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Third, clinicians’ prior beliefs about costs of each test might influence the
effectiveness of the intervention. Clinicians may have previously believed
that the cost of some tests was higher or lower than the displayed price.
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